These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 35045552

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival.
    Kurth J, Kretzschmar J, Aladwan H, Heuschkel M, Gummesson A, Bergner C, Kundt G, Hakenberg OW, Krause BJ, Schwarzenböck SM.
    Nucl Med Commun; 2021 Nov 01; 42(11):1217-1226. PubMed ID: 34424870
    [Abstract] [Full Text] [Related]

  • 4. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
    Santo G, Di Santo G, Zelger B, Virgolini I.
    Nuklearmedizin; 2024 Jun 01; 63(3):219-220. PubMed ID: 38190993
    [No Abstract] [Full Text] [Related]

  • 5. Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
    Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K.
    Radiology; 2024 Aug 01; 312(2):e233460. PubMed ID: 39162634
    [No Abstract] [Full Text] [Related]

  • 6. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
    Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M.
    Eur J Nucl Med Mol Imaging; 2019 May 01; 46(5):1063-1072. PubMed ID: 30569186
    [Abstract] [Full Text] [Related]

  • 7. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
    Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2022 Apr 01; 49(5):1584-1594. PubMed ID: 34725725
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
    Adnan A, Basu S.
    Nucl Med Commun; 2021 May 01; 42(5):566-574. PubMed ID: 33560718
    [Abstract] [Full Text] [Related]

  • 12. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
    Karyağar S, Güven O, Karyağar SS, Arici S, Selvi O, Geredeli Ç, Özülker F.
    Nucl Med Commun; 2021 Sep 01; 42(9):1011-1016. PubMed ID: 33958536
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T.
    Hartrampf PE, Hüttmann T, Seitz AK, Kübler H, Serfling SE, Higuchi T, Schlötelburg W, Michalski K, Gafita A, Rowe SP, Pomper MG, Buck AK, Werner RA.
    J Nucl Med; 2024 Apr 01; 65(4):560-565. PubMed ID: 38453363
    [Abstract] [Full Text] [Related]

  • 16. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
    Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, Stief C, Bartenstein P, Gratzke C, Lehner S, Rominger A.
    Oncotarget; 2017 Jan 10; 8(2):3581-3590. PubMed ID: 27683041
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.